home > about us > investors

Mesophotonics has raised two rounds of funding totalling £8.3m from top tier venture capital funds and corporate investors.

Auriga Partners

Auriga Partners is a French independent early stage VC fund. Auriga focuses on investments in high-potential, innovative start-ups in the areas of life sciences and information technology, mainly in Europe. To date Auriga manages about €200 million funds, split between three funds: European Medical Ventures, Auriga Ventures I and Auriga Ventures II.

For further information please refer to


BTG finds, develops and commercialises emerging technologies in the life and physical sciences. These innovations are protected by a strong portfolio of intellectual property that BTG develops and enhances. BTG then captures the value in these technologies through licensing and venturing activities.

From the origins of its business in 1949, BTG has commercialised major innovations such as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting protein, Campath® (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is on the London Stock Exchange under the symbol "BGC" and operates from offices in London and Philadelphia, with representation in Tokyo. BTG operates through wholly owned subsidiaries, BTG International Ltd and BTG International Inc in the UK and USA, respectively.

Further information on BTG can be found at

NIF Ventures Co Ltd

NIF Ventures Co Ltd is the venture capital arm of the Daiwa Securities Group of Japan and manages approximately $1 billion in venture capital funds. NIF has funded over 1,500 companies and assisted over 450 companies to exit since its foundation in 1982. Its primary focus is in information and communications technologies and life science VC investments. With offices in Japan, Taiwan, Singapore, and the United States, NIF offers worldwide representation.

Further information on NIF can be found at


Quester is one of the UK's leading independent venture capital groups specialising in the provision of finance and management support for growth companies at all stages of their life. Quester's focus is on early stage investments in information and communication technology, healthcare and life science companies. With its first rate track record, Quester has earned a reputation as one of the best UK based sources of venture capital. The Quester investment team manages approximately £300 million on behalf of major institutional investors, leading UK universities, and five quoted venture capital trusts.

For further information please refer to